Open an account

Ginkgo Bioworks Holdings

DNA · NYSE

$9.86−$0.21 (−2.09%)TodayMarket closed ·
Prev close $10.07

About DNA

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. The company is headquartered in Boston, Massachusetts and currently employs 485 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Employees
485
Headquarters
Boston, Massachusetts
Listed
Apr 19, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
investors.ginkgobioworks.com

DNA key statistics

Market cap
663.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.85M
Volume
2.49M
Open price
$10.04
High today
$10.38
Low today
$9.85
52 Week high
$18.22
52 Week low
$5.37

Ginkgo Bioworks Holdings (DNA) at a glance

Ginkgo Bioworks Holdings (DNA) last traded at $9.86, with a market cap of 663.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.85 and $10.38. The current price is 0.1% above the day's low and 5.0% below its high.

Volume so far is 2.49M shares, below the average of 3.85M shares a day.

Over the past year Ginkgo Bioworks Holdings has ranged from $5.37 to $18.22, and now sits 35% of the way up that range.

Ginkgo Bioworks Holdings met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.75 per share against an estimate of -$0.9191.

The average analyst price target is $7.14, 27.6% below the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold50.0%
  • Sell50.0%
Price target · 3 analystsAvg $7.14
Low
$5.05
Now
$9.86
High
$9.45

DNA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 25.0% on average.

  1. Q3 FY24: reported -$0.94 per share against an estimate of -$2.75
  2. Q4 FY24: reported -$2.00 per share against an estimate of -$1.79
  3. Q1 FY25: reported -$1.68 per share against an estimate of -$1.79
  4. Q2 FY25: reported -$1.10 per share against an estimate of -$1.58
  5. Q3 FY25: reported -$1.45 per share against an estimate of -$1.25
  6. Q4 FY25: reported -$1.41 per share against an estimate of -$1.47
  7. Q1 FY26: reported -$1.39 per share against an estimate of -$1.09
  8. Q2 FY26: reported -$0.75 per share against an estimate of -$0.9191

DNA news

  • Vandana Singh

    Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

  • Vandana Singh

    What's Going on With Ginkgo Bioworks Stock on Friday?

  • Avi Kapoor

    Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

  • Press releaseBusiness Wire

    Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program

  • Press releasePRNewswire

    Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop

  • Press releaseBusiness Wire

    Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

  • Press releaseBusiness Wire

    Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data

  • Press releaseBusiness Wire

    Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Similar companies

Companies in the same industry as Ginkgo Bioworks Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.